Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

neurogenics

- PMLiVE

Merck’s Keytruda scores in frontline lung cancer yet again

Drug improved overall survival as a monotherapy, which rival BMS’ Opdivo was unable to show

- PMLiVE

Incyte/Merck trial failure bodes ill for IDO class

The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone

AstraZeneca AZ

AZ pushes back data read-out from MYSTIC lung cancer trial

The delay could further undermine confidence in a positive outcome

- PMLiVE

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

The duo will start a series of clinical trials combining the multiple RTK inhibitor and Keytruda

AstraZeneca AZ

CHMP backs AZ’s Lynparza for ovarian cancer maintenance

Studies show that the drug reduced risk of disease progression

- PMLiVE

Merck buys cancer-killing virus firm Viralytics for $394m

It will acquire the Australian biotech’s lead cancer therapy Cavatek in the process

- PMLiVE

Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

Bavencio fails a key lung cancer trial

Bristol-Myers Squibb (BMS) building

BMS pens massive $3.6bn deal for Nektar cancer immunotherapy

Nektar’s NKTR-214 to be paired with Opdivo and Yervoy in a host of tumour types

- PMLiVE

Dr Fiona Marshall heads up MSD’s new UK research facility

She will be based in London and focus on early bioscience discovery

- PMLiVE

Merck chalks up another win for Keytruda in lung cancer

Becomes the first PD-1 inhibitor to improve OS in NSCLC patients when combined with chemo

- PMLiVE

AZ and Merck & Co get FDA breast cancer nod for Lynparza

It becomes the first PARP inhibitor to be approved outside ovarian cancer

- PMLiVE

Merck closes in on adjuvant melanoma indication for Keytruda

Its immunotherapy could catch up with BMS’ Opdivo if approved

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links